Innovative Eye Drop Treatment Expands to Switzerland and Liechtenstein
A groundbreaking treatment for post-operative inflammation and pain following eye surgery is making its way to Switzerland and Liechtenstein. Formosa Pharmaceuticals, a Taiwan-based biopharmaceutical company, has inked an exclusive licensing agreement with Medvisis Switzerland AG, a leading pharmaceutical company specializing in innovative therapies.
Revolutionizing Visual Recovery
The agreement grants Medvisis exclusive rights to commercialize APP13007, a specialized clobetasol propionate ophthalmic suspension, 0.05%, in both Swiss territories. This marks Formosa’s second foray into the European market, signifying a major milestone in the company’s global expansion initiatives.
APP13007, already successfully launched in the United States following FDA approval in March 2024, offers a new standard of care for patients undergoing ocular procedures. The innovative eye drop formula provides rapid relief from inflammation and pain, enhancing patient comfort during the crucial recovery period.
Strategic Partnership for Patient Benefit
The partnership leverages the complementary strengths of both companies. Formosa Pharmaceuticals brings its expertise in developing cutting-edge ophthalmic therapies, while Medvisis Switzerland AG boasts a deep understanding of the Swiss healthcare landscape.
“We are thrilled to partner with Medvisis, marking our second foothold in Europe,” said Erick Co, President and CEO of Formosa Pharmaceuticals. “Medvisis’ strong connections with their national regulatory agency and established network of key opinion leaders give us great confidence that the Swiss public will benefit from this novel and effective treatment for ocular surgery recovery.”
Manuel Ackermann, CEO of Medvisis Switzerland, echoed this sentiment: “We are pleased to provide patients with post-operative pain and inflammation following ocular surgery a new, best-in-class treatment option that leads to faster symptom relief. APP13007 is of great value to Swiss patients while it sets the foundation for Medvisis to build a strong portfolio of innovative ophthalmology solutions.”
Commitment to Excellence in Eye Care
The licensing agreement reflects a shared commitment to advancing patient care by delivering innovative ophthalmic solutions. APP13007’s arrival in Switzerland and Liechtenstein is anticipated to significantly improve post-surgical recovery by offering patients faster relief from discomfort, ultimately leading to a smoother and more comfortable visual healing process.
The agreement includes upfront payments, sales milestones, and additional considerations throughout the term, demonstrating a strong and collaborative partnership focused on bringing this transformative treatment to patients in need.
How will the collaboration between Formosa Pharmaceuticals and Medvisis ensure access to APP13007 for Swiss and Liechtensteiner patients?
## Interview: APP13007: A New Standard of Care for Eye Surgery Patients in Switzerland and Liechtenstein
**Host:** Welcome back to the show. Today, we’re discussing a breakthrough development in eye surgery aftercare here in Switzerland and neighboring Liechtenstein. Joining us to shed some light on this is [Guest Name], [Guest Title] at Medvisis Switzerland AG. Welcome to the show.
**Guest:** Thank you for having me. I’m thrilled to discuss this exciting advancement.
**Host:** For our viewers unfamiliar with this news, can you tell us about APP13007 and what makes it so groundbreaking?
**Guest:** APP13007 is a specialized eye drop formula containing clobetasol propionate, an anti-inflammatory agent. Developed by Formosa Pharmaceuticals, it’s specifically designed to provide rapid relief from inflammation and pain following eye surgery. Traditional post-operative treatments often involve oral medications with potential side effects, while APP13007 delivers targeted relief directly to the eyes in a convenient, easy-to-use drop form.
**Host:** I understand this treatment has already been successful in the US. How will its availability in Switzerland and Liechtenstein benefit patients here?
**Guest:** The introduction of APP13007 marks a significant step forward in patient care. It provides Swiss and Liechtensteiner patients undergoing ocular procedures with access to a novel, highly effective treatment that ultimately improves their recovery experience. With faster pain relief and reduced inflammation, patients can look forward to greater comfort and can return to their daily lives sooner.
**Host:** This partnership between Formosa Pharmaceuticals and Medvisis is clearly a strategic one. Can you tell us more about the goals of this collaboration?
**Guest:** Absolutely. This exclusive licensing agreement allows Medvisis to bring the benefits of APP13007 directly to patients in Switzerland and Liechtenstein. It reflects Formosa’s commitment to expanding access to its innovative therapies globally, while leveraging Medvisis’ strong presence and expertise in the Swiss pharmaceutical market.
**Host:** Lastly, what can patients expect in terms of availability and accessibility of APP13007 in the coming months?
**Guest:** We anticipate making APP13007 available to healthcare providers and patients in
Switzerland and Liechtenstein within the next few months. Our team is dedicated to ensuring a smooth launch and ensuring patients have access to this important treatment.
**Host:** Thank you for sharing this exciting news with us, [Guest Name]. I’m sure our viewers will be interested to learn more about APP13007.
**(For further information, please visit[Medvisis Switzerland AG website].)**
